Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What does the future hold for managed entry agreements?

This article was originally published in Scrip

Executive Summary

Managed entry agreements (MEAs), also known as risk-sharing schemes or coverage with evidence development, have become an increasingly common tool used to achieve market access in Europe. MEAs were initially designed to enable patient access to new medicines despite uncertainty regarding their effectiveness in the real-world setting. Although the first schemes involved more complex outcome-based agreements, such outcome-based schemes have given way to simpler discounts despite a global drive for payment for value, says Datamonitor Healthcare's lead analyst on market access, Dr Tijana Ignjatovic.

You may also be interested in...



Aetna: Entresto’s Label Enabled Outcome-Based Risk Share

Including the impact on hospitalizations in the label for Novartis's heart failure drug Entresto was critical to enable execution of outcome-based agreements. Such deals present an opportunity for pharma and payers to work together, but many challenges remain.

ISPOR Europe 2015: Are Spain And US The Ones To Watch For MEAs?

Despite the challenges with the implementation of managed entry agreements, the debate involving these complex market access routes is not abating. Speakers at the International Society for Pharmacoeconomics and Outcomes Research Europe meeting in Milan on 7–11 November 2015 discussed current experiences with such agreements across Europe, as they are about to make a bigger showing across the Atlantic.

Honing market access tactics given German drug assessment/price trends

Four years after its introduction, Germany's early benefit assessment process continues to make waves in the industry.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel